Items where authors include "Cairns, DA"

Article

McNamara, MG, Swain, J, Craig, Z et al. (21 more authors) (2023) NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. eClinicalMedicine, 60. 102015. ISSN 2589-5370

Hillmen, P, Pitchford, A, Bloor, A et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029

Platt, JR, Williams, CJM orcid.org/0000-0002-1574-653X, Craig, Z et al. (4 more authors) (2023) Personalising Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer: Protocols for the International Phase III FOxTROT2 and FOxTROT3 Randomised-Controlled Trials. Colorectal Disease. ISSN 1462-8910

Panopoulou, A, Cairns, DA orcid.org/0000-0002-2338-0179, Holroyd, AE et al. (13 more authors) (2022) Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients. Blood. ISSN 0006-4971

Cook, G orcid.org/0000-0001-7196-7364, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (1 more author) (2022) Defining FiTNEss for treatment for multiple myeloma. The Lancet Healthy Longevity, 3 (11). e729-e730. ISSN 2666-7568

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

D'Agostino, M, Cairns, DA orcid.org/0000-0002-2338-0179, Lahuerta, JJ et al. (28 more authors) (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 40 (29). pp. 3406-3420. ISSN 0732-183X

Snowden, JA, Ahmedzai, SH, Cox, A et al. (10 more authors) (2022) Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation, 57 (10). pp. 1507-1513. ISSN 0268-3369

Agbuduwe, C, Iqbal, G, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (12 more authors) (2022) Clinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials. Blood Advances, 6 (17). pp. 5113-5123. ISSN 2473-9529

de Tute, RM, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2022) Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 40 (25). pp. 2889-2900. ISSN 0732-183X

Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055

Paton, MF orcid.org/0000-0001-8517-4621, Gierula, J orcid.org/0000-0001-9588-191X, Lowry, JE et al. (9 more authors) (2021) Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial. PLoS ONE, 16 (12). e0259450. ISSN 1932-6203

Giles, HV, Cook, MA, Drayson, MT et al. (12 more authors) (2021) Redefining Non-measurable Multiple Myeloma Using Mass Spectrometry. Blood. ISSN 0006-4971

Royle, K-L and Cairns, DA orcid.org/0000-0002-2338-0179 (2021) The development and validation of prognostic models for overall survival in the presence of missing data in the training dataset: a strategy with a detailed example. Diagnostic and prognostic research, 5 (1). 14. 14-. ISSN 2397-7523

Hall, PS, Cairns, DA orcid.org/0000-0002-2338-0179 and Seymour, MT orcid.org/0000-0002-2441-9629 (2021) Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population—Reply. JAMA Oncology, 7 (11). 1725. ISSN 2374-2437

Croft, J, Ellis, S, Sherborne, AL et al. (19 more authors) (2021) Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 35 (7). pp. 2043-2053. ISSN 0887-6924

Weinhold, N, Salwender, HJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (15 more authors) (2021) Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients. Haematologica. ISSN 0390-6078

Hall, PS, Swinson, D, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (32 more authors) (2021) Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA oncology, 7 (6). pp. 869-877. ISSN 2374-2437

Morris, TCM, Drake, MB, Kettle, PJ et al. (12 more authors) (2021) How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. Clinical hematology international, 3 (1). pp. 27-33. ISSN 2590-0048

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 192 (5). bjh.16945. pp. 853-868. ISSN 0007-1048

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Rana, R, Cockwell, P, Drayson, M et al. (8 more authors) (2020) Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Advances, 4 (22). pp. 5836-5845. ISSN 2473-9529

Shah, V, Sherborne, AL, Johnson, DC et al. (16 more authors) (2020) Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 34. pp. 3091-3096. ISSN 0887-6924

Jackson, GH, Davies, FE, Pawlyn, C et al. (20 more authors) (2020) Lenalidomide Before And After ASCT For Transplant-Eligible Patients Of All Ages In The Randomized, Phase III, Myeloma XI Trial. Haematologica. haematol.2020.247130. ISSN 0390-6078

Bradbury, CA, Craig, Z orcid.org/0000-0001-9930-6648, Cook, G orcid.org/0000-0003-0223-3652 et al. (14 more authors) (2020) Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials. Blood. ISSN 0006-4971

Boyle, EM, Ashby, C, Tytarenko, R et al. (25 more authors) (2020) BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 26 (10). pp. 2422-2432. ISSN 1078-0432

Craig, Z orcid.org/0000-0001-9930-6648, Swain, J, Batman, E et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 6 (12). e616-e629. ISSN 2352-3026

Paton, MF orcid.org/0000-0001-8517-4621, Gierula, J orcid.org/0000-0001-9588-191X, Jamil, HA et al. (9 more authors) (2019) Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. BMJ open, 9 (7). e028613. ISSN 2044-6055

Ahmedzai, SH, Snowden, JA, Ashcroft, AJ et al. (19 more authors) (2019) Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. Journal of Clinical Oncology, 37 (19). pp. 1617-1628. ISSN 0732-183X

Jones, JR, Weinhold, N, Ashby, C et al. (19 more authors) (2019) Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 104 (7). pp. 1440-1450. ISSN 0390-6078

Cook, G, Royle, K-L, O'Connor, S et al. (20 more authors) (2019) The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. British Journal of Haematology, 185 (3). pp. 450-467. ISSN 0007-1048

Westbrook, JA, Wood, SL, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2019) Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of pathology, 247 (3). pp. 381-391. ISSN 0022-3417

Cook, G orcid.org/0000-0003-0223-3652, Royle, K-L, Pawlyn, C et al. (10 more authors) (2019) A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematology, 6 (3). pp. 154-166. ISSN 2352-3026

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (1). pp. 57-73. ISSN 1470-2045

Shah, V, Johnson, DC, Sherborne, AL et al. (19 more authors) (2018) Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 132 (23). pp. 2465-2469. ISSN 0006-4971

Gay, F, Jackson, G, Rosiñol, L et al. (28 more authors) (2018) Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. JAMA Oncology, 4 (10). pp. 1389-1397. ISSN 2374-2437

Royle, K-L, Gregory, WM orcid.org/0000-0003-2641-8416, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (8 more authors) (2018) Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. British Journal of Haematology, 182 (6). pp. 816-829. ISSN 0007-1048

Striha, A orcid.org/0000-0003-3363-8417, Ashcroft, AJ, Hockaday, A et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. p. 169. ISSN 1745-6215

Gierula, J orcid.org/0000-0001-9588-191X, Paton, MF, Lowry, JE et al. (8 more authors) (2018) Rate-Response Programming Tailored to the Force-Frequency Relationship Improves Exercise Tolerance in Chronic Heart Failure. JACC: Heart Failure, 6 (2). pp. 105-113. ISSN 2213-1779

Campbell, JP, Heaney, JLJ, Pandya, S et al. (10 more authors) (2017) Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematology. ISSN 2352-3026

Heaney, JLJ, Campbell, JP, Griffin, AE et al. (8 more authors) (2017) Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. British Journal of Haematology, 178 (2). pp. 220-230. ISSN 0007-1048

Shah, V, Sherborne, AL, Walker, BA et al. (19 more authors) (2017) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1,905 trial patients. Leukemia, 32. pp. 102-110. ISSN 0887-6924

Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385

Pawlyn, C, Kaiser, MF, Heuck, C et al. (20 more authors) (2016) The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clinical Cancer Research, 22 (23). pp. 5783-5794. ISSN 1078-0432

Greenwood, JP, Ripley, DP, Berry, C et al. (14 more authors) (2016) Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates : The CE-MARC 2 Randomized Clinical Trial. JAMA. pp. 1051-1060. ISSN 1538-3598

Greenwood, JP, Ripley, DP, Berry, C et al. (14 more authors) (2016) Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial. Journal of the American Medical Association, 316 (10). pp. 1051-1060. ISSN 0098-7484

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (16 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology, 3 (7). e340-e351.

Parrish, C, Morris, CTCM, Williams, CD et al. (13 more authors) (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22 (6). pp. 1009-1016. ISSN 1083-8791

Cubbon, RM, Witte, KK, Kearney, LC et al. (11 more authors) (2016) Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification. Heart, 102 (10). pp. 735-740. ISSN 1355-6037

Jamil, HA, Gierula, J, Paton, MF et al. (6 more authors) (2016) Chronotropic incompetence does not limit exercise capacity in chronic heart failure. Journal of the American College of Cardiology, 67 (16). pp. 1885-1896. ISSN 0735-1097

Westbrook, JA, Cairns, DA orcid.org/0000-0002-2338-0179, Peng, J et al. (10 more authors) (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. JNCI: Journal of the National Cancer Institute, 108 (4). ISSN 0027-8874

Walker, BA, Boyle, EM, Wardell, CP et al. (24 more authors) (2015) Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 33 (33). pp. 3911-3920. ISSN 0732-183X

Mihailovich, M, Bremang, M, Spadotto, V et al. (9 more authors) (2015) MiR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nature Communications, 6. 8725. ISSN 2041-1723

Hepburn, S, Cairns, DA, Jackson, D et al. (7 more authors) (2015) An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis. PROTEOMICS - Clinical Applications, 9 (5-6). pp. 507-521. ISSN 1862-8346

Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2015) APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 6. ARTN 6997.

Welberry Smith, MP, Zougman, A orcid.org/0000-0002-7168-1339, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (9 more authors) (2013) Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney International, 84 (6). pp. 1214-1225. ISSN 0085-2538

Brüning-Richardson, A, Bond, J, Alsiary, R et al. (9 more authors) (2012) NuMA overexpression in epithelial ovarian cancer. PLoS One, 7 (6). ARTN e38945. e38945 - ?. ISSN 1932-6203

Smith, MP, Wood, SL, Zougman, A et al. (7 more authors) (2011) A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top‐down and bottom‐up proteomic analyses. Proteomics, 11 (11). pp. 2222-2235. ISSN 1615-9853

Bruning-Richardson, A orcid.org/0000-0002-9862-9805, Bond, J orcid.org/0000-0001-5390-5688, Alsiary, R et al. (9 more authors) (2011) ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. British Journal of Cancer, 104 (10). pp. 1602-1610. ISSN 0007-0920

Monograph

Selby, PJ, Banks, RE orcid.org/0000-0002-0042-8715, Gregory, W orcid.org/0000-0003-2641-8416 et al. (50 more authors) (2018) Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Report. NIHR Journals Library , Southampton, UK. ISSN 2050-4322

Hall, PS, Mitchell, ED orcid.org/0000-0002-2833-1632, Smith, AF orcid.org/0000-0001-7709-1869 et al. (9 more authors) (2018) The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation. Report. NIHR Journals Library , Health Technology Assessment, Volume 22, Issue 32. ISSN 1366-5278

Proceedings Paper

Williams, C, Emmerson, J, Beggs, AD et al. (12 more authors) (2022) A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442). In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting, 03-07 Jun 2022, Online & Chicago, IL, USA. American Society of Clinical Oncology .

McNamara, MG, Swain, J, Craig, Z et al. (11 more authors) (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2014) Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. In: BLOOD. 56th ASH Annual Meeting 2014, 06-09 Dec 2014, San Francisco, California, USA. American Society of Hematology .